search
Back to results

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Primary Purpose

Advanced Cancer, Metastatic Cancer, Ovarian Cancer

Status
Recruiting
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
ART0380
Gemcitabine
Irinotecan
Sponsored by
Artios Pharma Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Advanced Cancer focused on measuring Loss of Ataxia Telangiectasia Mutated (ATM) protein

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

General Inclusion Criteria:

  • Signed written informed consent
  • Have not received a previous treatment targeting the ATR/CHK1 pathway
  • Discontinued all previous treatments for cancer for at least 21 days or 5 half-lives, whichever is shorter, and recovered from the acute effects of therapy to CTCAE Grade ≤1. Palliative radiotherapy must have completed 1 week prior to start of study treatment.
  • If patients have a known germline BRCA mutation or a cancer with a somatic BRCA mutations or which is HRD positive and for which there is an approved PARP inhibitor, participants should have received such treatment before participating in the study unless contra-indicated
  • At least 1 radiologically evaluable lesion (measurable and/or non-measurable) that can be assessed at baseline and is suitable for repeated radiological evaluation by RECIST v1.1 or Prostate Cancer Working Group-3 Guidelines (PCWG-3)
  • Acceptable hematologic, renal, hepatic, and coagulation functions independent of transfusions and granulocyte colony-stimulating factor
  • Non-irradiated tumor tissue sample (archival or newly obtained core biopsy of a tumor lesion) available for submission for analysis via immunohistochemistry (IHC) for loss of ATM protein
  • Female patients of childbearing potential and male patients with female partners of childbearing potential are required to use highly effective contraception plus one barrier method during their participation in the study and for 4 or 16 weeks respectively following the last dose. For male and female patients given gemcitabine or irinotecan, highly effective contraception plus one barrier method must be used from study entry until 6 months after the last dose of study treatment. Male patients are required to refrain from donating sperm during their participation in the study and for 6 months following last dose.
  • Estimated life expectancy of ≥12 weeks
  • Reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures

Additional inclusion criteria for participants in dose escalation (Part A1):

  • Advanced or metastatic cancer which is refractory to standard therapies, or for which no standard therapies exist, or for which the investigator feels no other active therapy is required for the duration of the study
  • Performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) scale

Additional inclusion criteria for participants in dose escalation (Part A2):

  • Advanced or metastatic cancer for which gemcitabine is an appropriate treatment. Prior treatment with gemcitabine is permitted.
  • Performance status of 0-2 on the ECOG scale

Additional inclusion criteria for participants in dose escalation (Part A3):

  • Advanced or metastatic cancer for which irinotecan is an appropriate treatment. Prior treatment with irinotecan is permitted.
  • Performance status of 0-1 on the ECOG scale

Additional inclusion criteria for participants in dose expansion (Part B1):

  • Patients with advanced or metastatic solid tumors with alterations to the ATM gene likely to predict for loss of ATM protein
  • Have at least 1 measurable lesion assessable using standard techniques by RECIST v1.1
  • Performance status of 0-1 on the ECOG scale

Additional inclusion criteria for participants in dose expansion (Part B2):

  • Females with histologically-confirmed diagnosis of high grade serous carcinoma of the ovary, fallopian tube or primary peritoneum that is not amenable to curative therapy
  • Platinum-resistant disease, defined as disease progression within 6 months of last receipt of platinum-based chemotherapy. Patients must not have had primary platinum-refractory disease (disease that progressed during first-line or second-line platinum-based therapy).
  • No more than one prior regimen in the platinum-resistant setting. Hormonal therapies and antiangiogenic therapies (as single agents) and PARP inhibitors used as maintenance therapy are not considered as separate lines of therapy. Patients should have previously received bevacizumab and chemotherapy unless contra-indicated.
  • Have not received prior treatment with gemcitabine unless administered in combination with a platinum with no disease progression within 12 months after completion of that regimen
  • Have at least 1 measurable lesion assessable using standard techniques by RECIST v1.1
  • Performance status of 0-1 on the on the ECOG scale

General Exclusion Criteria:

  • Women who are pregnant, breast feeding, or who plan to become pregnant while in the study or within 4 weeks after the last administration of study treatment
  • Men who plan to father a child while in the study or within 16 weeks after the last administration of study treatment
  • Serious concomitant systemic disorder that would compromise the participants ability to adhere to the protocol including: one or more opportunistic HIV/AIDs-related infections within the past 12 months, hepatitis B virus, or hepatitis C virus; known history of clinical diagnosis of tuberculosis; malignancy prior to the one currently being treated that is not in remission
  • Evidence of interstitial lung disease or pneumonitis (whether symptomatic or asymptomatic). Patients with a previous history of these conditions which have resolved may be permitted to enter the study after discussion with the medical monitor (applicable to US population only).
  • Moderate or severe cardiovascular disease
  • Valvulopathy that is severe, moderate, or deemed clinically significant
  • Documented major electrocardiogram (ECG) abnormalities which are clinically significant
  • Symptomatic or uncontrolled brain metastases, spinal cord compression, or leptomeningeal disease requiring concurrent treatment
  • Received a live vaccine within 30 days before the first dose of study treatment
  • History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate
  • Recent major surgery within 4 weeks prior to entry into the study or minor surgery within 1 week of entry into the study
  • Significant bleeding disorder or vasculitis or had a Grade ≥3 bleeding episode within 12 weeks prior to enrollment
  • Currently enrolled in a clinical trial involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study

Additional exclusion criteria for participants in dose escalation (Part A3):

  • Patients who are homozygous for the UGT1A1 *6 or *28. (UGT1A1 7/7 genotype), or simultaneously heterozygous for the UGT1A1 *6 and *28. (UGT1A1 7/7 genotype)
  • Patients receiving inhibitors of UGT1A1 within 2 weeks before the first dose of study treatment

Sites / Locations

  • University of Alabama at BirminghamRecruiting
  • University of Arkansas - Winthrop P. Rockefeller Cancer InstituteRecruiting
  • Sarah Cannon Research Institute at HealthONERecruiting
  • Florida Cancer SpecialistsRecruiting
  • Florida Cancer Specialists
  • Florida Cancer SpecialistsRecruiting
  • Florida Cancer SpecialistsRecruiting
  • Stephenson Cancer CenterRecruiting
  • Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research OrganizationRecruiting
  • Tennessee Oncology, PLLCRecruiting
  • Tennessee OncologyRecruiting
  • Mary Crowley Cancer ResearchRecruiting
  • Hospital Clínico Universitario Virgen de la ArrixacaRecruiting
  • Clínica Universidad de NavarraRecruiting
  • Hospital Teresa Herrera (CHUAC)Recruiting
  • Institut Català d'Oncologia Badalona - Hospital Germans Trias i PujolRecruiting
  • Hospital Clinic de BarcelonaRecruiting
  • ICO HospitaletRecruiting
  • Hospital Universitario Reina Sofia de CórdobaRecruiting
  • Hospital Universitari Doctor Josep Trueta- ICO de GironaRecruiting
  • Hospital General Universitario Gregorio MarañónRecruiting
  • MD Anderson Cancer Center (MadridRecruiting
  • Hospital Clinico San CarlosRecruiting
  • Hospital Universitario 12 de OctubreRecruiting
  • Hospital Virgen del RocíoRecruiting
  • Incliva Biomedical Research Institute, University of ValenciaRecruiting
  • Hospital Universitario Miguel ServetRecruiting
  • Sarah Cannon Research Institute UKRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

Part A1

Part A2

Part A3

Part B1

Part B2

Arm Description

Part A1 will evaluate intermittent and continuous dosing of ART0380 monotherapy. Treatment will be given in 21-day cycles. Up to 50 participants will participate in this dose-escalation arm.

Part A2 will evaluate intermittent dosing of ART0380 in combination with gemcitabine in 21-day cycles. Up to 21 participants will participate in this dose escalation arm.

Part A3 will evaluate intermittent dosing of ART0380 in combination with irinotecan in 21-day cycles. Up to approximately 12 participants will participate in this dose escalation arm.

In Part B1, up to 3 cohorts making up to a total of approximately 90 participants with solid cancers with alterations in the ATM (ataxia-telangiectasia mutated) gene likely to predict for loss of ATM protein will be treated with either ART0380 monotherapy Or ART0380 in combination with irinotecan Or ART0380 in combination with gemcitabine

In Part B2, up to 60 participants with high grade serous ovarian, primary peritoneal, or fallopian tube carcinoma will be randomized (open-label) 1:1 to either ART0380 in combination with gemcitabine or gemcitabine alone.

Outcomes

Primary Outcome Measures

Part A: Maximum tolerated dose (MTD) by the number of participants with dose limiting toxicities (DLTs) from ART0380 monotherapy and in combination with gemcitabine or irinotecan
Part B1: Number of participants with adverse events following administration of ART0380 monotherapy and in combination with gemcitabine or irinotecan monotherapy and in combination with gemcitabine or irinotecan
Safety reported as incidence of adverse events
Part B2: Progression free survival by RECIST 1.1 in participants receiving ART0380 in combination with gemcitabine or gemcitabine alone
Progression free survival (PFS)

Secondary Outcome Measures

Part B2: Number of participants with adverse events following administration of ART0380 in combination with gemcitabine or gemcitabine alone
Pharmacokinetic Analysis (single dose): determine the plasma concentration of ART0380 when given alone and in combination
Pharmacokinetic Analysis (multiple dose): determine the plasma concentration of ART0380 when given alone and in combination
Pharmacokinetic Analysis: Renal clearance of ART0380
Parts A1, A2, A3, B1, and B2: Objective response rate based on RECIST 1.1
Parts A1, A2, A3, B1, and B2: Duration of response based on RECIST 1.1
Parts A1, A2, A3 and B1: Progression free survival based on RECIST 1.1
Assess tumor biopsies by immunohistochemistry (IHC) for loss of Ataxia Telangiectasia Mutated (ATM) protein
Where available archival tumor samples will be obtained for analysis of loss of ATM protein by IHC. If an archival tumor sample is not available, a pre-dose tumor biopsy must be taken.

Full Information

First Posted
December 1, 2020
Last Updated
August 8, 2023
Sponsor
Artios Pharma Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT04657068
Brief Title
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Official Title
A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 13, 2020 (Actual)
Primary Completion Date
June 2025 (Anticipated)
Study Completion Date
June 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Artios Pharma Ltd

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan Learn more about the side effects of ART0380 alone and in combination with gemcitabine or irinotecan Learn more about the effectiveness of ART0380 alone and in combination with gemcitabine or irinotecan
Detailed Description
ART0380 is a new investigational medicinal product that is a potent and selective inhibitor of Ataxia telangiectasia and Rad3-related (ATR). ART0380 is being developed as an oral anti-cancer agent for the treatment of participants with cancers that harbor defects in deoxyribonucleic acid (DNA) repair and in combination with agents including those that cause DNA damage. This study is an open-label Phase I/IIa study designed to evaluate the safety, tolerability, PK and preliminary efficacy of ART0380 as monotherapy or in combination with gemcitabine or irinotecan in participants with advanced or metastatic solid tumors, advanced or solid tumors that fail to express Ataxia-Telangiectasia Mutated protein kinase (ATM) by immunohistochemistry, and high grade serous ovarian, primary peritoneal or fallopian tube carcinoma.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Keywords
Loss of Ataxia Telangiectasia Mutated (ATM) protein

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
242 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Part A1
Arm Type
Experimental
Arm Description
Part A1 will evaluate intermittent and continuous dosing of ART0380 monotherapy. Treatment will be given in 21-day cycles. Up to 50 participants will participate in this dose-escalation arm.
Arm Title
Part A2
Arm Type
Experimental
Arm Description
Part A2 will evaluate intermittent dosing of ART0380 in combination with gemcitabine in 21-day cycles. Up to 21 participants will participate in this dose escalation arm.
Arm Title
Part A3
Arm Type
Experimental
Arm Description
Part A3 will evaluate intermittent dosing of ART0380 in combination with irinotecan in 21-day cycles. Up to approximately 12 participants will participate in this dose escalation arm.
Arm Title
Part B1
Arm Type
Experimental
Arm Description
In Part B1, up to 3 cohorts making up to a total of approximately 90 participants with solid cancers with alterations in the ATM (ataxia-telangiectasia mutated) gene likely to predict for loss of ATM protein will be treated with either ART0380 monotherapy Or ART0380 in combination with irinotecan Or ART0380 in combination with gemcitabine
Arm Title
Part B2
Arm Type
Experimental
Arm Description
In Part B2, up to 60 participants with high grade serous ovarian, primary peritoneal, or fallopian tube carcinoma will be randomized (open-label) 1:1 to either ART0380 in combination with gemcitabine or gemcitabine alone.
Intervention Type
Drug
Intervention Name(s)
ART0380
Intervention Description
Participants will receive ART0380 by mouth either intermittently (either once daily 3 days on, 4 days off; days 2-4 and 9-11;or days 1-3 and 8-10) or continuously (once daily each day) in 21 day cycles.
Intervention Type
Drug
Intervention Name(s)
Gemcitabine
Other Intervention Name(s)
Gemzar
Intervention Description
Gemcitabine will be administered on Days 1 and 8 of a 21-day cycle.
Intervention Type
Drug
Intervention Name(s)
Irinotecan
Other Intervention Name(s)
Camptosar, Camptothecin-11
Intervention Description
Irinotecan will be administered as a 90-minute infusion on Days 1 and 8 of a 21 day cycle.
Primary Outcome Measure Information:
Title
Part A: Maximum tolerated dose (MTD) by the number of participants with dose limiting toxicities (DLTs) from ART0380 monotherapy and in combination with gemcitabine or irinotecan
Time Frame
From Cycle 0 Day -2 to Cycle 1 Day 21. Each cycle is 21 days.
Title
Part B1: Number of participants with adverse events following administration of ART0380 monotherapy and in combination with gemcitabine or irinotecan monotherapy and in combination with gemcitabine or irinotecan
Description
Safety reported as incidence of adverse events
Time Frame
From Cycle 1 Day 1 until up to 30 days after the last dose of ART0380. Each cycle is 21 days.
Title
Part B2: Progression free survival by RECIST 1.1 in participants receiving ART0380 in combination with gemcitabine or gemcitabine alone
Description
Progression free survival (PFS)
Time Frame
Every 6 weeks from Cycle 1 Day 1 for 18 weeks, then every 9 weeks up to approximately 24 months. Each cycle is 21 days.
Secondary Outcome Measure Information:
Title
Part B2: Number of participants with adverse events following administration of ART0380 in combination with gemcitabine or gemcitabine alone
Time Frame
From Cycle 1 Day 1 until up to 30 days after the last dose of ART0380 or gemcitabine. Each cycle is 21 days.
Title
Pharmacokinetic Analysis (single dose): determine the plasma concentration of ART0380 when given alone and in combination
Time Frame
PK will be measured at each cycle from Cycle 0 to Cycle 4. Each cycle is 21 days.
Title
Pharmacokinetic Analysis (multiple dose): determine the plasma concentration of ART0380 when given alone and in combination
Time Frame
PK will be measured at each cycle from Cycle 0 to Cycle 4. Each cycle is 21 days.
Title
Pharmacokinetic Analysis: Renal clearance of ART0380
Time Frame
Urine PK will be measured during Cycle 1. Cycle 1 is 21 days.
Title
Parts A1, A2, A3, B1, and B2: Objective response rate based on RECIST 1.1
Time Frame
Every 6 weeks from Cycle 1 Day 1 for 18 weeks, then every 9 weeks up to approximately 24 months. Each cycle is 21 days.
Title
Parts A1, A2, A3, B1, and B2: Duration of response based on RECIST 1.1
Time Frame
Every 6 weeks from Cycle 1 Day 1 for 18 weeks, then every 9 weeks up to approximately 24 months. Each cycle is 21 days.
Title
Parts A1, A2, A3 and B1: Progression free survival based on RECIST 1.1
Time Frame
Every 6 weeks from Cycle 1 Day 1 for 18 weeks, then every 9 weeks up to approximately 24 months. Each cycle is 21 days.
Title
Assess tumor biopsies by immunohistochemistry (IHC) for loss of Ataxia Telangiectasia Mutated (ATM) protein
Description
Where available archival tumor samples will be obtained for analysis of loss of ATM protein by IHC. If an archival tumor sample is not available, a pre-dose tumor biopsy must be taken.
Time Frame
Prior to dosing on Cycle 1 Day 1

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
General Inclusion Criteria: Signed written informed consent Have not received a previous treatment targeting the ATR/CHK1 pathway Discontinued all previous treatments for cancer for at least 21 days or 5 half-lives, whichever is shorter, and recovered from the acute effects of therapy to CTCAE Grade ≤1. Palliative radiotherapy must have completed 1 week prior to start of study treatment. If patients have a known germline BRCA mutation or a cancer with a somatic BRCA mutations or which is HRD positive and for which there is an approved PARP inhibitor, participants should have received such treatment before participating in the study unless contra-indicated At least 1 radiologically evaluable lesion (measurable and/or non-measurable) that can be assessed at baseline and is suitable for repeated radiological evaluation by RECIST v1.1 or Prostate Cancer Working Group-3 Guidelines (PCWG-3) Acceptable hematologic, renal, hepatic, and coagulation functions independent of transfusions and granulocyte colony-stimulating factor Non-irradiated tumor tissue sample (archival or newly obtained core biopsy of a tumor lesion) available for submission for analysis. Female patients of childbearing potential and male patients with female partners of childbearing potential are required to use highly effective contraception plus one barrier method during their participation in the study and for 7 months and 5 months respectively following the last dose. For male and female patients given gemcitabine or irinotecan, highly effective contraception plus one barrier method must be used from study entry until 6 months after the last dose of study treatment. Male patients are required to refrain from donating sperm and female patients are required to refrain from donating eggs, during their participation in the study and for 6 months following last dose. Estimated life expectancy of ≥12 weeks Reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures Additional inclusion criteria for participants in dose escalation (Part A1): Advanced or metastatic cancer which is refractory to standard therapies, or for which no standard therapies exist, or for which the investigator feels no other active therapy is required for the duration of the study Performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) scale Additional inclusion criteria for participants in dose escalation (Part A2): Advanced or metastatic cancer for which gemcitabine is an appropriate treatment. Prior treatment with gemcitabine is permitted. Performance status of 0-2 on the ECOG scale Additional inclusion criteria for participants in dose escalation (Part A3): Advanced or metastatic cancer for which irinotecan is an appropriate treatment. Prior treatment with irinotecan is permitted. Performance status of 0-1 on the ECOG scale Additional inclusion criteria for participants in dose expansion (Part B1): Patients with advanced or metastatic solid tumors with alterations to the ATM gene likely to predict for loss of ATM protein Have at least 1 measurable lesion assessable using standard techniques by RECIST v1.1 Performance status of 0-1 on the ECOG scale For France only ART0380 Monotherapy; Patient that is not eligible for curative treatment, for whom all standard of care therapies have failed and no therapies known to provide clinical benefit are available. Combination arms; Patients for which irinotecan or gemcitabine is an appropriate treatment. Prior treatment with irinotecan or gemcitabine is permitted. Additional inclusion criteria for participants in dose expansion (Part B2): Patients with a known germline BRCA mutation, or a cancer with a known somatic BRCA mutation, or which is known to be HRD positive, and for which there is an approved PARP inhibitor should have received such treatment before participating in the study, unless contra-indicated. Females with histologically-confirmed diagnosis of high grade serous carcinoma of the ovary, fallopian tube or primary peritoneum that is not amenable to curative therapy Platinum-resistant disease, defined as disease progression within 6 months of last receipt of platinum-based chemotherapy. Patients must not have had primary platinum-refractory disease (disease that progressed during first-line platinum-based therapy). No more than one prior regimen in the platinum-resistant setting. Hormonal therapies and antiangiogenic therapies (as single agents) and PARP inhibitors used as maintenance therapy are not considered as separate lines of therapy. Patients should have previously received bevacizumab and chemotherapy unless contra-indicated. Have not received prior treatment with gemcitabine unless administered in combination with a platinum with no disease progression within 12 months after completion of that regimen Have at least 1 measurable lesion assessable using standard techniques by RECIST v1.1 Performance status of 0-1 on the on the ECOG scale General Exclusion Criteria: Women who are pregnant, breast feeding, or who plan to become pregnant while in the study or within 7 months after the last administration of study treatment Men who plan to father a child while in the study or within5 months after the last administration of study treatment Serious concomitant systemic disorder that would compromise the participants ability to adhere to the protocol including: one or more opportunistic HIV/AIDs-related infections within the past 12 months, hepatitis B virus, or hepatitis C virus; known history of clinical diagnosis of tuberculosis; malignancy prior to the one currently being treated that is not in remission Have ongoing interstitial lung disease or pneumonitis (whether symptomatic or asymptomatic). Moderate or severe cardiovascular disease Valvulopathy that is severe, moderate, or deemed clinically significant Documented major electrocardiogram (ECG) abnormalities which are clinically significant Symptomatic or uncontrolled brain metastases, spinal cord compression, or leptomeningeal disease requiring concurrent treatment Received a live vaccine within 30 days before the first dose of study treatment History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate Recent major surgery within 4 weeks prior to entry into the study or minor surgery within 1 week of entry into the study Significant bleeding disorder or vasculitis or had a Grade ≥3 bleeding episode within 12 weeks prior to enrollment Currently enrolled in a clinical trial involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study Additional exclusion criteria for participants in dose escalation (Part A3 and B1 in combination with irinotecan): Patients who are known to be homozygous for the UGT1A1 *6 or *28. (UGT1A1 7/7 genotype), or simultaneously heterozygous for the UGT1A1 *6 and *28. (UGT1A1 7/7 genotype) Patients receiving inhibitors of UGT1A1 within 2 weeks before the first dose of study treatment
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sarah Cannon Development Innovations
Phone
844-710-6157
Email
CANN.InnovationsMedical@sarahcannon.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Melissa Johnson, MD
Organizational Affiliation
Tennessee Oncology
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Antonio Gonzalez, MD, PHD
Organizational Affiliation
Clinica Universidad de Navarra, Madrid
Official's Role
Study Chair
Facility Information:
Facility Name
University of Alabama at Birmingham
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35294-3300
Country
United States
Individual Site Status
Recruiting
Facility Name
University of Arkansas - Winthrop P. Rockefeller Cancer Institute
City
Little Rock
State/Province
Arkansas
ZIP/Postal Code
72205
Country
United States
Individual Site Status
Recruiting
Facility Name
Sarah Cannon Research Institute at HealthONE
City
Denver
State/Province
Colorado
ZIP/Postal Code
80218
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gerald Falchook, MD
Facility Name
Florida Cancer Specialists
City
Fort Myers
State/Province
Florida
ZIP/Postal Code
33901
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fadi Kayali, MD
Facility Name
Florida Cancer Specialists
City
Orlando
State/Province
Florida
ZIP/Postal Code
32827
Country
United States
Individual Site Status
Completed
Facility Name
Florida Cancer Specialists
City
Sarasota
State/Province
Florida
ZIP/Postal Code
34232
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Manish Patel, MD
Facility Name
Florida Cancer Specialists
City
West Palm Beach
State/Province
Florida
ZIP/Postal Code
33401
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Barry Scott Berman, MD
Facility Name
Stephenson Cancer Center
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73104
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kathleen Moore, MD
Facility Name
Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Babar Bashir, MD
Facility Name
Tennessee Oncology, PLLC
City
Chattanooga
State/Province
Tennessee
ZIP/Postal Code
37404
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Edward Riker Arrowsmith, MD
Facility Name
Tennessee Oncology
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37203
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Melissa Johnson, MD
Facility Name
Mary Crowley Cancer Research
City
Dallas
State/Province
Texas
ZIP/Postal Code
75230
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Minal Barve, MD
Facility Name
Hospital Clínico Universitario Virgen de la Arrixaca
City
El Palmar
State/Province
Murcia
ZIP/Postal Code
30120
Country
Spain
Individual Site Status
Recruiting
Facility Name
Clínica Universidad de Navarra
City
Madrid
State/Province
Planta -2
ZIP/Postal Code
28027
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Teresa Herrera (CHUAC)
City
A Coruña
ZIP/Postal Code
15006
Country
Spain
Individual Site Status
Recruiting
Facility Name
Institut Català d'Oncologia Badalona - Hospital Germans Trias i Pujol
City
Badalona
ZIP/Postal Code
08916
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Clinic de Barcelona
City
Barcelona
ZIP/Postal Code
08036
Country
Spain
Individual Site Status
Recruiting
Facility Name
ICO Hospitalet
City
Barcelona
ZIP/Postal Code
08903
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario Reina Sofia de Córdoba
City
Córdoba
ZIP/Postal Code
14004
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitari Doctor Josep Trueta- ICO de Girona
City
Girona
ZIP/Postal Code
17007
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital General Universitario Gregorio Marañón
City
Madrid
ZIP/Postal Code
28007
Country
Spain
Individual Site Status
Recruiting
Facility Name
MD Anderson Cancer Center (Madrid
City
Madrid
ZIP/Postal Code
28033
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Clinico San Carlos
City
Madrid
ZIP/Postal Code
28040
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario 12 de Octubre
City
Madrid
ZIP/Postal Code
28041
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Virgen del Rocío
City
Sevilla
ZIP/Postal Code
41013
Country
Spain
Individual Site Status
Recruiting
Facility Name
Incliva Biomedical Research Institute, University of Valencia
City
Valencia
ZIP/Postal Code
46010
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario Miguel Servet
City
Zaragoza
ZIP/Postal Code
50009
Country
Spain
Individual Site Status
Recruiting
Facility Name
Sarah Cannon Research Institute UK
City
London
ZIP/Postal Code
W1G 6AD
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Elisa Fontana

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

We'll reach out to this number within 24 hrs